Physician-Led Expertise. Faster Start-Up. Specialized Ophthalmology Sites.
Discuss Your Program →Developing a breakthrough ophthalmic therapy is difficult enough. Running the clinical trial shouldn't be.
Many sponsors face the same obstacles: long regulatory timelines, rising study costs, competition for experienced sites, and patient recruitment challenges that can delay development by months or even years.
For ophthalmology sponsors, choosing the right CRO is about much more than operational support. It requires a partner that understands the science, the clinical realities, and the unique demands of ophthalmology research.
This is why aCROss Medical created aCROss Vision - a dedicated ophthalmology division focused exclusively on supporting ophthalmic clinical trials across Georgia, Armenia, Israel, and Uzbekistan.
Led by ophthalmologist Yoram Solberg, MD, PhD, our monitors are all ophthalmologists who combine deep therapeutic expertise with hands-on operational experience to help sponsors move efficiently from feasibility to first patient enrolled and ultimately to successful study completion.
The Challenge
Ophthalmology is one of the most technically demanding areas of clinical research. Unlike many therapeutic areas, success depends not only on operational execution but also on a deep understanding of ophthalmic pathology, clinical practice, and evolving technologies.
Sponsors need sites capable of generating high-quality data while maintaining efficient recruitment and protocol compliance. That combination is becoming increasingly difficult to find...
Our clinics:
Our Reach
As clinical development becomes more competitive, sponsors are increasingly looking beyond saturated research markets. Our regions offer a compelling combination of speed, quality, and patient access.
Across Georgia, Armenia, and Uzbekistan, investigators have access to large populations of treatment-naïve patients - often translating into faster enrollment and more predictable recruitment performance.
Track Record
Our experience spans the full spectrum of ophthalmic clinical research - pharmaceuticals, biologics, medical devices, surgical innovations, and advanced therapies. We have supported numerous innovative studies from US, European, APAC, and Israeli sponsors.
Multicenter Randomized Controlled Trial - BELKIN Vision (now part of Alcon)
A prospective, multicenter, randomized trial evaluating Direct Selective Laser Trabeculoplasty (DSLT) versus conventional SLT for the treatment of open-angle glaucoma and ocular hypertension.
aCROss Medical managed all operational activities from site qualification and regulatory submissions through monitoring and data management. Results were published in Ophthalmology - one of the world's leading journals in the field.
Publication: Randomized Noninferiority Trial of Direct Selective Laser Trabeculoplasty - GLAUrious Study · Ophthalmology, 2025
ClinicalTrials.gov: NCT04758598
"BELKIN Vision collaborated with aCROss Medical on several projects, and the experience was consistently productive and efficient. The team was responsive, professional, and worked seamlessly on study, regulatory, and site interactions."- BELKIN Vision (now part of Alcon)
Single-Arm Clinical Investigation - CorNeat Vision
A single-arm, pivotal, open-label clinical investigation evaluating the safety and performance of CorNeat EverPatch - the world's first non-degradable, fully synthetic tissue substitute for ophthalmic surgery - used for concealment of glaucoma tube shunts and other artificial ocular implants.
aCROss Medical managed all site operations, including regulatory and ethics submissions, clinical monitoring, and 12-month follow-up coordination. EverPatch integrates subconjunctivally using CorNeat's proprietary EverMatrix™ nano-fabric technology, eliminating dependence on donor tissue or biological grafts.
Publication: Early Postoperative Conjunctival Complications of Surgically Implanted CorNeat EverPatch Devices · Ophthalmology, 2025
ClinicalTrials.gov: NCT05469867
"Working with aCROss Medical felt less like managing a vendor and more like having an extension of our own team."- Sponsor Partner, CorNeat Vision Corneal Implant Program
Device Safety and Performance Trial - EyeYon Medical
Supporting the clinical development of EndoArt® - the world's first synthetic endothelial layer for the treatment of chronic bullous keratopathy and corneal edema. EndoArt replaces the failing human endothelium with a flexible hydrophilic-acrylic disc, offering a permanent, donor-independent alternative to traditional DSAEK and DMEK procedures.
aCROss Medical managed the clinical sites in their entirety - from site activation, ethics committee submissions, and patient recruitment through clinical monitoring. The EndoArt has since received CE Mark and FDA IDE approval for an expanded US pivotal study, building on clinical evidence gathered across multiple global centers.
Publication: EndoArt Phase 2 Safety and Performance Study · Cornea, 2025
ClinicalTrials.gov: NCT05139771
Our Difference
At aCROss Vision, our clinical operations are guided by ophthalmologists.
Most CROs operate through project managers and monitors who coordinate between sponsors, investigators, and vendors. At aCROss Vision, our clinical operations are guided by ophthalmologists who understand the science behind the protocol and the realities of clinical practice.